Jay Patel
Nephrology · Greensboro, NCNPI 1013034727
Payments from drug & device makers
Across 510 payments — averaging $51.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$16K
- Amgen$3K
- AstraZeneca$2K
- Mallinckrodt Hospital Products Inc.$1K
- Otsuka America Pharmaceutical, Inc.$872
- Vifor Pharma, Inc.$709
- plus $4K from 31 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 38 | $15,540 |
| Amgen(2 entities) | 74 | $2,697 |
| AstraZeneca(2 entities) | 94 | $1,664 |
| Mallinckrodt Hospital Products Inc. | 33 | $1,066 |
| Otsuka America Pharmaceutical, Inc. | 43 | $872 |
| Vifor Pharma, Inc. | 39 | $709 |
| Travere Therapeutics, Inc. | 27 | $578 |
| Calliditas Therapeutics US Inc. | 16 | $457 |
| GSK | 23 | $391 |
| ANI Pharmaceuticals, Inc. | 17 | $277 |
| Mallinckrodt Enterprises LLC | 8 | $225 |
| Daiichi Sankyo Inc. | 10 | $198 |
| Novo Nordisk | 12 | $190 |
| Aurinia Pharma U.S., Inc. | 8 | $184 |
| Fresenius USA Marketing, Inc. | 11 | $179 |
| Novartis | 9 | $178 |
| Nxstage Medical, Inc. | 3 | $151 |
| AbbVie | 1 | $125 |
| OPKO Pharmaceuticals, LLC | 8 | $120 |
| Ardelyx, Inc. | 6 | $118 |
| Scpharmaceuticals Inc. | 5 | $112 |
| Medtronic | 2 | $73 |
| Alnylam Pharmaceuticals Inc. | 2 | $53 |
| Boehringer Ingelheim | 3 | $47 |
| Akebia Therapeutics Inc | 2 | $39 |
| AMAG Pharmaceuticals, Inc. | 3 | $37 |
| Sanofi | 2 | $33 |
| Boston Scientific | 2 | $33 |
| Mozarc Medical US LLC | 1 | $23 |
| Shire North American Group Inc | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| Pfizer | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| La Jolla Pharmaceutical Company | 1 | $13 |
How this compares
$26,505 in reported general payments places this provider in the 80th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Greensboro
- Daniel EdmonstonDurham$9.9M
- Gregory GreenwoodWinston-Salem$4.1M
- Barry FreedmanWinston Salem$3.5M
- Manuel MonteroNew Bern$2.5M
- Rekha JohnKinston$2.3M
- Nauman ShahidGreenville$2M
- Eric KirkWilmington$1.7M
- Amy MottlSanford$1.6M
- Amarnath KathresalDurham$1.6M
- Koithara Varkey ThomasJacksonville$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.